EuroXpand SIGNED
EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EuroXpand project word cloud
Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.
Project "EuroXpand" data sheet
The following table provides information about the project.
| Coordinator |
CELLPROTHERA
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 5˙000˙000 € |
| EC max contribution | 5˙000˙000 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2021-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CELLPROTHERA | FR (MULHOUSE) | coordinator | 5˙000˙000.00 |
Map
Project objective
Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.
Deliverables
| Communication material (brochures, web…) | Documents, reports | 2020-02-12 17:33:26 |
| Press Release - Project kick-off | Documents, reports | 2020-02-12 17:33:28 |
Take a look to the deliverables list in detail: detailed list of EuroXpand deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
RESHAPE (2019)
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More